Answers are grounded in this paper and cite their sources.
Elevated carbon dioxide (CO 2 ) levels in both the inspired gas mixture and arterial blood are independently physiologically significant when working in sealed environments, including space exploration. This issue is therefore highly relevant to aerospace medicine, diving medicine, and environmental medicine. Hypercapnia is generally defined as a rise in PaCO 2 (arterial partial pressure of carbon dioxide) above 45 mmHg. It develops due to alveolar hypoventilation, increased dead space, excessive CO 2 production, or exogenous CO 2 intake. The biological effect is mediated by shifts in blood pH and is determined not only by CO 2 concentration but also by the duration of exposure, the rate of PaCO 2 rise, the degree of acidemia, blood O 2 content, physical exertion, temperature, and the baseline status of the respiratory, cardiovascular, and renal systems. Therefore, ambient CO 2 concentration and PaCO 2 cannot be used as interchangeable indicators. The value of a molecular biomarker for hypercapnia lies not only in its correlation with elevated CO 2 levels but also in its potential to reveal episodic or chronic hypercapnia—and, ideally, prior hypercapnic exposure—when direct measurement is not feasible. This review aims to systematize the health risks associated with hypercapnia, outline the temporal sequence of compensatory and deleterious reactions, and identify candidate protein markers or molecular effectors of the CO 2 response for situations in which direct measurement of PaCO 2 is not feasible.
No takes yet. Share an insight, caveat, or question.
Pastushkova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: